Research in context {#sec0001}
===================

Evidence before this study {#sec0002}
--------------------------

There has been a rising interest in treating locally advanced rectal cancer (LARC) with total neoadjuvant therapy (TNT) where the adjuvant chemotherapy is delivered preoperatively. However, whether patients' outcomes such as overall survival are improved when using TNT compared to standard neoadjuvant chemoradiation therapy followed by surgery with or without adjuvant chemotherapy (nCRT) is not currently known. Most studies are retrospective in nature from single institutions and describe the use of TNT in a highly selected patient population. Furthermore, there is no published randomised evidence to guide the use of TNT for LARC. Therefore, evidence we considered prior to our analysis were extrapolated from articles queried from Pubmed. Our search criteria included all Pubmed listed articles until February of 2019, which reported on the use of TNT for LARC. Search terms utilised include "rectal cancer" AND "total neoadjuvant therapy" or "neoadjuvant chemotherapy" and a filter limiting species to "humans". The current evidence suggests that TNT may result in improved pathological complete response (pCR) with inconclusive data on overall survival benefit.

Added value of this study {#sec0003}
-------------------------

In this large study, we demonstrate that was no difference in overall survival between patients with LARC receiving TNT and those receiving nCRT. Furthermore, we utilised multivariate and propensity-based matching to account for potential biases associated with retrospective data. By utilizing a national wide cancer database, our data best represents the LARC population. Of further significance, we were able to demonstrate that while TNT resulted in slightly higher pCR or negative circumferential resection margin (CRM) rates, this was not statistically significant.

Implications of all the available evidence {#sec0004}
------------------------------------------

While the use on TNT in the management of LARC is currently on the rise, there was no clear improvement in OS or pCR rates when using TNT in this and other studies. As TNT can result in overtreatment for some patients with LARC, our data suggests awaiting definitive randomised trial results showing a clear benefit for TNT before its routine use in all patients with LARC.

1. Introduction {#sec0005}
===============

It is estimated that 44,180 new cases of rectal cancer will be diagnosed in the United States in 2019 [@bib0001]. One standard of care for locally advanced rectal cancer involves chemoradiation therapy (CRT) delivered in the neoadjuvant setting with preoperative 5-fluorouracil- or capecitabine-based chemotherapy combined with standard fractionated radiotherapy (RT), total mesorectal excision, and adjuvant chemotherapy, henceforth referred to as nCRT \[[@bib0002],[@bib0003]\]. However, a significant proportion of patients treated with curative neoadjuvant CRT and surgery do not received their planned adjuvant chemotherapy, with less than 50% of eligible patients receiving the full course adjuvant chemotherapy, due to patient refusal or post-operative complications \[[@bib0002],[@bib0004], [@bib0005], [@bib0006], [@bib0007], [@bib0008]\]. As a result, there has been an interest in the possibility of delivering chemotherapy before the initiation of neoadjuvant CRT, referred to as total neoadjuvant therapy (TNT). Two on-going clinical trials are exploring the potential benefits of this regimen. In the PROSPECT trial, patients in the study arm receive six cycles of FOLFOX chemotherapy and are then re-staged to determine if they still need pre-operative CRT based on their response to the FOLFOX [@bib0009]. This trial aims to prevent the use of radiation therapy in a subset of patients \[[@bib0009],[@bib0010]\]. In the NRG- GI002 phase II TNT trial, patients receive eight cycles of mFOLFOX6 followed by RT in combination with either capecitabine or capecitabine + veliparib [@bib0010]. Other potential benefits of TNT in addition to improved compliance include early eradication of micrometastasis, higher rates of clinical complete response and improving rates of negative circumferential resection margin (CRM). While these trials will provide invaluable information regarding TNT regimen, they may not answer the question "is TNT better than standard treatment". We therefore conducted a large retrospective analysis using the National Cancer Database (NCDB) to determine adoption of TNT and compare its outcomes to nCRT in patients with locally advanced rectal adenocarcinoma, clinically defined as cT3/4 or node positive disease.

2. Materials andmethods {#sec0006}
=======================

2.1. Patient population {#sec0007}
-----------------------

A total of 264,257 patients with rectal cancer diagnosed between 2004 and 2015 were identified using the NCDB. No patient identifiers or otherwise identifiable health information is provided through the NCBD. We limited our analysis to patients with invasive adenocarcinoma who had locally advanced disease, which was defined as clinical stage M0 and T3 or T4 or any T stage with nodal involvement. We further excluded patients if they were \<18 years old, did not receive chemotherapy or RT before surgery, did not receive surgery within a year of RT, diagnosis was not confirmed histologically, did not receive treatments at the reporting facility, or received only ablative surgical procedures or local excision. To minimise immortality bias, patients were excluded if last contacts were made within 8 weeks of definitive surgery.

Given the limited data available in the NCDB (no information on specific chemotherapy agents or number of cycles e.g.), patients were considered to have received TNT if they received RT and multi-agent chemotherapy before definitive surgery, RT was started at least two months after the induction of chemotherapy, and no chemotherapy was given after definitive surgery, based on comparable studies in the past \[[@bib0011],[@bib0012]\]. Patients were considered to have received nCRT if they received RT and chemotherapy before definitive surgery, and RT and chemotherapy were started less than 2 weeks apart. Patients not meeting either of these two definitions were not included in the analysis.

2.2. Propensity score matching {#sec0008}
------------------------------

We utilised propensity score matching to minimise effects of selection bias between treatment types by balancing characteristics of patients receiving TNT and nCRT. Variables included in propensity matching were age, gender, year of diagnosis, race and ethnicity, Charlson-Deyo Comorbidity Score, clinical T and N stage, tumour grade, facility type, urban status, insurance status, and income. These variables chosen to generate the propensity scores were determined through Cox proportional hazards modelling and multivariable logistic regression as important confounders due to their association with either OS or pCR. Matching was performed with the nearest neighbour approach using STATA v. 14•2 (StataCorp, College Station, TX), with a calliper of 0•001.

Given the different numbers of patients receiving each type of treatment, two-to-one matching with replacement was performed as this provides improved statistical power compared to a one-to-one match. A ten-to-one matching was included as a sensitivity analysis to test if added statistical power through including more patients receiving nCRT in the analysis would change the results. Two other one-way sensitivity analyses were performed to evaluate the impact on the results from varying definitions of the nCRT comparison group. In the first one, the definition of nCRT was narrowed to only include patients who received adjuvant chemotherapy, whereas in the other sensitivity analysis the nCRT cohort was limited to only include those who received multi-agent chemotherapy in either the neoadjuvant or the adjuvant setting.

2.3. Statistical analysis {#sec0009}
-------------------------

Multivariable Cox proportional hazards regression and Kaplan-Meier curves with both logrank and Wilcoxon--Breslow tests were used to evaluate any difference in OS between TNT and nCRT. Multivariable logistic regression was used to determine the association between treatment type and pCR rates and between treatment type and negative CRM rates. Cox proportional hazards regression was performed to determine the association between pCR and OS in each cohort. The proportional hazards assumption was tested and verified in the post-propensity matching cohort based on Schoenfeld residuals. T-tests and Chi-square tests were used to evaluate the distribution of patient characteristics and potential confounders between the TNT and nCRT treatment types, before and after propensity matching. OS rates at different time points were compared between the two treatment groups using Z-tests comparing two proportions.

3. Results {#sec0010}
==========

A total of 42,118 patients were identified to have locally advanced adenocarcinoma of the rectum diagnosed between 2004 and 2015 and met our inclusion criteria ([Fig. 1](#fig0001){ref-type="fig"}). Among those patients, 421 received treatment that met our criteria for TNT, whereas treatment for 38,584 patients met the criteria for nCRT ([Fig. 1](#fig0001){ref-type="fig"}). The characteristics of patients receiving the two treatment types were summarised in [Table 1](#tbl0001){ref-type="table"}. The mean age of patients receiving TNT was 54•4 y, whereas that of patients receiving nCRT was 59•9 y (*p* \< 0•001). TNT was more frequently used after 2010 with 78•8% patients receiving TNT diagnosed after 2010 while this proportion was 51•3% in those receiving nCRT (*p* \< 0•001). Patients receiving TNT had better Charlson-Deyo co-morbidity score (≥2 1•4% vs. 3•7%, *p* \< 0•01), but a more advanced T stage (T4 16•4% vs. 6•3%, *p* \< 0•001) and N stage (N+ 69•9% vs. 44•9%, *p* \< 0•001). A significantly higher proportion of patients receiving TNT were treated at an academic facility compared to those receiving nCRT (71•0% vs. 34•8%, *p* \< 0•001).Fig. 1CONSORT diagram illustrating the patient selection for this study. TNT was defined as (1) RT started at least 60 days after chemotherapy (2) Multi-agent chemotherapy (3) No chemotherapy after surgery. nCRT was defined as (1) Not receiving TNT (2) RT started within 14 days of chemotherapy induction.Fig 1Table 1Patient characteristics in the unmatched cohort.Table 1Baseline characteristicsAll patientsTNTnCRT*p*-value(*n* = 39,005)(*n* = 421)(*n* = 38,584)Age (y), mean ± SD59.9 ± 12.154.4 ± 11.559.9 ± 12.1**\<0.001**Sex, *n* (%)  Male24,266 (62.2)262 (62.2)24,004 (62.2)0.99  Female14,739 (37.8)159 (37.8)14,580 (37.8)Year of diagnosis, *n* (%) 2004--20055,446 (14.0)35 (8.3)5,411 (14.0)**\<0.001** 2006--20076,586 (16.9)30 (7.1)6,556 (17.0) 2008--20096,832 (17.5)24 (5.7)6,808 (17.6) 2010--20117,186 (18.4)72 (17.1)7,114 (18.4) 2012--20138,344 (21.4)152 (36.1)8,192 (21.2) 2014--20154,611 (11.8)108 (25.6)4,503 (11.7)Race, *n* (%)  non-Hispanic White32,279 (82.8)329 (78.2)31,950 (82.8)**0.009**  non-Hispanic Black2,930 (7.5)29 (6.9)2,901 (7.5)  Hispanic1,958 (5.0)34 (8.1)1,924 (5.0)  Asian1,128 (2.9)17 (4.0)1,111 (2.9)  Other/Unknown710 (1.8)12 (2.8)698 (1.8)Charlson-Deyo co-morbidity score, n (%) 031,206 (80.0)359 (85.3)30,847 (80.0)**0.008** 16,366 (16.3)56 (13.3)6,310 (16.4) ≥21,433 (3.7)6 (1.4)1,427 (3.7)T stage, *n* (%) ≤T21,974 (5.1)16 (3.8)1,958 (5.1)**\<0.001**  T329,190 (74.9)302 (71.7)28,888 (74.9)  T42,502 (6.4)69 (16.4)2,433 (6.3)  Tx5,323 (13.6)34 (8.1)5,289 (13.7)N stage, *n* (%)  N015,505 (39.8)90 (21.4)15,415 (40.0)**\<0.001**  N115,179 (38.9)226 (53.7)14,953 (38.8)  N22,437 (6.2)68 (16.2)2,369 (6.1)  Nx5,878 (15.1)37 (8.8)5,841 (15.1)Grade, *n* (%) Well/moderately differentiated29,106 (74.6)324 (77.0)28,782 (74.6)0.48 Poorly differentiated/anaplastic4,245 (10.9)44 (10.5)4,201 (10.9) Unknown5,654 (14.5)53 (12.6)5,601 (14.5)Total radiation dose (Gy), median (25th-75th percentile)50.40\
(50.40-50.40)50.40\
(50.00-50.40)50.40\
(50.40-50.40)**\<0.001**Type of facility, *n* (%) Non-academic24,147 (64.9)110 (29.0)24,037 (65.2)**\<0.001** Academic13,080 (35.1)269 (71.0)12,811 (34.8)Urban status, *n* (%) Metropolitan area30,159 (77.3)347 (82.4)29,812 (77.3)**\<0.001** Metropolitan-adjacent area6,790 (17.4)24 (5.7)6,766 (17.5) Rural area992 (2.5)4 (1.0)988 (2.6) Unknown1,064 (2.7)46 (10.9)1,018 (2.6)Median income quartiles, *n* (%)  \<\$38,0006,681 (17.3)45 (10.8)6,636 (17.4)**\<0.001**  \$38,000-\$47,9999,680 (25.0)74 (17.7)9,606 (25.1)  \$48,000-\$62,99910,626 (27.5)96 (23.0)10,530 (27.5)  ≥\$63,00011,689 (30.2)203 (48.6)11,486 (30.0)Medical insurance type Not insured1,776 (4.6)14 (3.3)1,762 (4.6)**\<0.001** Private insurance/managed care20,204 (51.8)292 (69.4)19,912 (51.6) Medicaid2,469 (6.3)36 (8.6)2,433 (6.3) Medicare13, 434 (34.4)67 (15.9)13,367 (34.6) Other government563 (1.4)8 (1.9)555 (1.4) Insurance status unknown559 (1.4)4 (1.0)555 (1.4)Circumferential resection margin, n (%) Positive1,027 (6.1)10 (4.7)1,017 (6.1)0.39 Negative15,827 (93.9)203 (95.3)15,624 (93.9)[^1]

In the multivariable logistic regression model assessing which factors were associated with patient assignment of each treatment type, diagnosis after 2012, clinical stage \>2, treatment at academic facilities, and higher median income quartiles were associated with higher likelihood of receiving TNT (*p* \< 0•001 for all). Age, gender, Charlson-Deyo co-morbidity score, and tumour grade were not associated with the likelihood of receiving TNT (Supplementary Table 1).

Univariable Cox proportional hazards regression showed that female gender, diagnosis after 2010, treatment at an academic facility, and higher median income quartile were each associated with better survival outcome, whereas age greater than 65 years, the presence of comorbid conditions, high tumour grade, and non-metropolitan residency correlated with worse survival outcome (all *p* \< 0•001, Supplementary Table 2).

There was no difference in OS between TNT and nCRT in the unmatched cohort (logrank *p* = 0•85; Wilcoxon-Breslow *p* = 0•59, [Fig. 2](#fig0002){ref-type="fig"}), with 10,415 deaths (27%) among patients receiving nCRT and 84 deaths (20%) among those receiving TNT. The 3-year, 4-year, and 5-year OS rates in each arm were 88•4% vs. 86•9%, 81•7% vs. 81•1%, and 73•8% vs. 75•8% (reported as TNT vs. nCRT, all *p* \> 0•36), respectively, with a median follow-up time of 30•9 months for patients receiving TNT and 48•2 months for those receiving nCRT. After propensity matching, 707 nCRT patients and 372 TNT patients were identified as the matched cohort, balanced in the distribution of demographics and disease characteristics ([Table 2](#tbl0002){ref-type="table"}). In the matched cohort, TNT was not associated with improved OS (logrank *p* = 0•16; Wilcoxon-Breslow *p* = 0•80, [Fig. 2](#fig0002){ref-type="fig"}), with 122 deaths among patients receiving nCRT (17%) and 75 deaths among those receiving TNT (20%). The 3-year, 4-year, and 5-year OS rates for patients receiving TNT and nCRT were 88•5% vs. 88•9%, 82•0% vs. 83•9%, and 73•6% vs. 78•5%, respectively (all *p* \> 0•20). The median follow-up time was 31•0 months for patients receiving TNT and 33•7 months for those receiving nCRT. Median time from diagnosis to surgery was 8•4 months (IQR: 7•2--9•2 months) for TNT compared to 4•4 months (IQR: 3•9--5•2 months) for nCRT. The median elapsed time between the initiation of chemotherapy to the start of RT was 17 weeks in patients receiving TNT.Fig. 2The overall survival of patients receiving TNT and nCRT for the unmatched and matched cohorts. Number of patients at risk zero, two, four, six, eight, and ten years from diagnosis are displayed at the bottom. No statistically significant difference was found in either cohort (logrank *p* = 0•85; Wilcoxon-Breslow *p* = 0•59 for the unmatched cohort, and logrank *p* = 0•16; Wilcoxon-Breslow *p* = 0•80 for the matched cohort).Fig 2Table 2Patient characteristics in the propensity matched cohort.Table 2Patient characteristicsAll patientsTNTnCRT*p*-value(*n* = 1,079)(*n* = 372)(*n* = 707)Age (y), mean ± SD57.0 ± 9.856.8 ± 9.657.1 ± 10.00.61Sex, n (%)  Male668 (61.9)231 (62.1)437 (61.8)0.93  Female411 (38.1)141 (37.9)270 (38.2)Year of diagnosis, *n* (%) 2004--200585 (7.9)30 (8.1)55 (7.8)0.88 2006--200791 (8.4)28 (7.5)63 (8.9) 2008--200971 (6.6)21 (5.6)50 (7.1) 2010--2011165 (15.3)60 (16.1)105 (14.8) 2012--2013397 (36.8)137 (36.8)260 (36.8) 2014--2015270(25.0)96 (25.8)174 (24.6)Race, *n* (%)  non-Hispanic White850 (78.8)294 (79.0)556 (78.6)0.67  non-Hispanic Black66 (6.1)27 (7.3)39 (5.5)  Hispanic89 (8.2)28 (7.5)61 (8.6)  Asian52 (4.8)15 (4.0)37 (5.2)  Other/Unknown22 (2.0)8 (2.2)14 (2.0)Charlson-Deyo co-morbidity score, n (%) 0908 (84.2)314 (84.4)594 (84.0)0.98 1154 (14.3)52 (14.0)102 (14.4) ≥217 (1.6)6 (1.6)11 (1.6)T stage, n (%) ≤T238 (3.5)15 (4.0)23 (3.2)0.88  T3771 (71.5)265 (71.2)506 (71.6)  T4193 (17.9)64 (17.2)129 (18.2)  Tx77 (7.1)28 (7.5)49 (6.9)N stage, *n* (%)  N0282 (26.1)88 (23.7)194 (27.4)0.57  N1543 (50.3)196 (52.7)347 (49.1)  N2160 (14.8)56 (15.0)104 (14.7)  Nx94 (8.7)32 (8.6)62 (8.8)Grade, *n* (%) Well/moderately differentiated844 (78.2)284 (76.3)560 (79.2)0.56 Poorly differentiated/anaplastic104 (9.6)39 (10.5)65 (9.2) Unknown131 (12.1)49 (13.2)82 (11.6)Total radiation dose (Gy), median (25th-75^th^ percentile)50.40\
(50.14-50.40)50.40\
(50.00-50.40)50.40\
(50.40-50.40)**\<0.001**Type of facility, *n* (%) Non-academic331 (30.7)108 (29.0)223 (31.5)0.40 Academic748 (69.3)264 (71.0)484 (68.5)Urban status, *n* (%) Metropolitan area900 (83.4)313 (84.1)587 (83.0)0.81 Metropolitan-adjacent area64 (5.9)23 (6.2)41 (5.8) Rural area10 (0.9)4 (1.1)6 (0.8) Unknown105 (9.7)32 (8.6)73 (10.3)Median income quartiles, n (%)  \<\$38,000125 (11.6)41 (11.0)84 (11.9)0.82  \$38,000-\$47,999205 (19.0)66 (17.7)139 (19.7)  \$48,000-\$62,999255 (23.6)91 (24.5)164 (23.2)  ≥\$63,000494 (45.8)174 (46.8)320 (45.3)Medical insurance type Not insured39 (3.6)12 (3.2)27 (3.8)0.81 Private insurance/managed care722 (66.9)254 (68.3)468 (66.2) Medicaid97 (9.0)32 (8.6)65 (9.2) Medicare193 (17.9)64 (17.2)129 (18.2) Other government23 (2.1)7 (1.9)16 (2.3) Insurance status unknown5 (0.5)3 (0.8)2 (0.3)Circumferential resection margin, n (%) Positive40 (6.3)9 (4.7)31 (6.9)0.30 Negative598 (93.7)95.3 (95.3)417 (93.1)

Limited information regarding toxicity is available through the NCDB. In the propensity-matched cohort (*n* = 372 for TNT and *n* = 707 for nCRT), the 90-day mortality rate after surgery was 0.54% for TNT and 0.57% for nCRT (*p* = 0.95).

On multivariable analysis, there was no statistically significant difference in OS between TNT and nCRT (HR = 1•21, *p* = 0•25; [Table 3](#tbl0003){ref-type="table"}). In this multivariable Cox proportional hazards regression model, higher median income quartile was associated with better OS (*p* = 0•002), whereas age ≥65 years was associated with worse OS (*p* = 0•001). The associations between survival and gender, Charlson-Deyo co-morbidity score, clinical stage, tumour grade, and type of facility were not significant ([Table 3](#tbl0003){ref-type="table"}).Table 3Multivariable Cox proportional hazards regression for overall survival in the matched cohort.Table 3All patients(*n* = 1,079)VariableHazard ratio*p*-value(95% CIs)Treatment group (TNT vs. nCRT)1.21 (0.87, 1.69)0.25Age (≥ 65 yr vs. \< 65 yr)1.86 (1.30, 2.65)**0.001**Sex (female vs. male)0.85 (0.60, 1.19)0.34Charlson-Deyo co-morbidity score 01.0 (ref)0.30 11.37 (0.91, 2.08) ≥21.29 (0.46, 3.59)Clinical stage (\> 2 vs. ≤ 2)1.39 (0.96, 1.99)0.077Grade Well/moderately differentiated1.0 (ref)0.099 Poorly differentiated/anaplastic1.52 (0.95, 2.43) Unknown0.76 (0.44, 1.30)Type of facility (academic vs. non-academic)0.96 (0.68, 1.35)0.80Median income quartiles  \<\$38,0001.0 (ref)**0.002**  \$38,000-\$47,9990.90 (0.55, 1.47)  \$48,000-\$62,9990.48 (0.28, 0.82)  ≥\$63,0000.51 (0.32, 0.82)[^2]

Among patients receiving TNT, 16•9% achieved pCR compared to 13•1% among patients receiving nCRT (*p* = 0•12). Multivariable logistic regression did not find that TNT was significantly associated with pCR (OR = 1•36, *p* = 0•13). The negative CRM rate was 95•3% among patients receiving TNT, compared to 93•1% among patients receiving nCRT (*p* = 0•30). In multivariable logistic regression, TNT was found to be associated with higher rate of negative CRM (OR = 1•77), but this difference was not significant statistically (*p* = 0•19). In both cohorts, having pCR at time of surgery was associated with better OS (HR = 0•11, *p* = 0•002 in the nCRT cohort and HR=0•10, *p* = 0•025 in the TNT cohort).

In the sensitivity analysis with a ten-to-one propensity matching, 372 patients receiving TNT were matched with 2946 patients receiving nCRT. Similar to the two-to-one match, a multivariable analysis showed no statistically significant difference in OS between patients receiving TNT and nCRT (HR = 1•16, *p* = 0•28; Supplementary Table 3).

In a second sensitivity analysis limiting the nCRT cohort to patients who received both neoadjuvant CRT and adjuvant chemotherapy, 330 patients receiving TNT were matched with 564 patients receiving nCRT. On multivariable analysis, there was no statistically significant difference in OS between patients receiving TNT and nCRT (HR = 0•86, *p* = 0•39; Supplementary Table 4).

In a third sensitivity analysis with the nCRT cohort consisting of patients receiving multi-agent chemotherapy in both the neoadjuvant and adjuvant setting, 323 patients receiving TNT were matched with 537 patients receiving nCRT. On multivariable analysis, there was no statistically significant difference in OS between patients receiving TNT and nCRT (HR = 1•36, *p* = 0•12; Supplementary Table 5).

4. Discussion {#sec0011}
=============

In this large retrospective cohort study using the NCDB, we found no significant difference in OS between patients with locally advanced rectal adenocarcinoma who were treated with TNT and those who were treated with nCRT. This result persisted after patients were propensity matched for characteristics that could confound the association with OS and to account for treatment selection bias. We also found a slightly higher pCR and negative CRM rate among patients receiving TNT, but these differences were not statistically significant and did not translate into better OS.

These results are consistent with those reported in the Spanish GCR-3 phase II randomised trial [@bib0013] and another phase II randomised trial reported by Maréchal et al. [@bib0014], where no difference was found in pCR and OS. Authors of GCR-3 pointed out that the study might be underpowered to detect any significant difference in OS. Although this may be true, our study did not find a statistically significant difference despite including a larger number of patients. This trial protocol mandated adjuvant chemotherapy in the nCRT treatment, which when tested in sensitivity analysis did not alter the results in our study. Of note, the study by Maréchal et al was closed prematurely due to perceived futility and the group receiving TNT experienced higher Grade 3/4 toxicity compared to the nCRT group [@bib0014]. The pCR rates in our study (TNT 16•9% and nCRT 13•1%) are also comparable to those reported in the GCR-3 study (TNT 14•3% and nCRT 13•5%) as well as the retrospective study by Cercek et al. (TNT 18% and nCRT 17%) \[[@bib0011],[@bib0013]\]. The European EXPERT-C trial also showed a similar pCR rate (15% in the study arm with 4 cycles of capecitabine/oxaliplatin as induction chemotherapy) [@bib0015].

Given the lack of clear improvement in pCR rates, CRM rates and OS for the use of TNT in this and other studies, the results from the on-going PROSPECT and NRG-GI002 clinical trials will be crucial in helping refine the TNT regimen to maximise the benefits of preoperative therapy. While current national guidelines such as NCCN allow TNT for any T3-4 or node positive rectal cancer patients, it is possible that some of the lower risk patients maybe overtreated using TNT, especially the stage II rectal cancer patients who may not benefit as much from the addition of chemotherapy.

TNT can be defined in a few different ways depending on when chemotherapy is given in relation to chemoradiation, but prior to surgery. Due to the limited information available in the NCDB regarding chemotherapy agents and timing between chemotherapy and radiation, our definition follows that of TNT with induction chemotherapy followed by chemoradiation before surgery. A phase II trial from the German Rectal Cancer Study Group comparing two different TNT sequences demonstrated a higher pCR rate after TNT with consolidation chemotherapy compared to TNT with induction chemotherapy, although this could have been impacted by the prolonged interval between completion of chemoradiation and surgery [@bib0016]. Similar results were also found in another non-randomised trial where there were higher pCR rates with increasing number of cycles of chemotherapy, following chemoradiation [@bib0017].

Limitations of our study include its retrospective nature and lack of detailed information regarding specific chemotherapy agents used and the number of cycles administered. Another limitation is the potential selection bias associated with treatment assignment. We accounted for this source of bias by propensity matching, balancing potential confounders between the two treatment groups. Year of diagnosis, clinical stage, facility type, urban status, income and insurance type were found to be associated with receiving TNT and none of those characteristics are different between the two treatment groups after propensity matching. Nevertheless, there are some factors that were not captured in the NCDB, such as tumour location in rectum, depth of extramural tumour involvement and vascular invasion, treating centre expertise, and thus cannot be fully accounted for by propensity matching. TNT was more commonly performed at academic centres (71% vs. 35%) in typically healthier patients (Charlson co-morbidity score of zero in 85% vs. 80% of patients). These factors would tend to favour TNT over nCRT, but despite this we still do not find a significant difference in survival between the two treatment groups.

In conclusion, our study found no survival benefit or significant improvement in pCR rates associated with TNT treatment compared to nCRT.
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[^1]: Bold font indicates statistically significant difference with *p* \< 0.05.
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